MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
bluebird bio, Inc. (NASDAQ: BLUE)*
Organization & Developments: Bluebird
Parents
bluebird bio, Inc. (NASDAQ: BLUE)*
Children
*At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options
*bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia.
*Bluebird Bio’s Approach Represents a True Paradigm Shift in the Treatment of Severe Genetic Diseases by Eliminating the Potential Complications Associated with Donor Cell Transplantation and Presenting a One-time Transformative Therapy.
*Development of innovative gene therapies for severe genetic disorders
*Formerly, Genetix Pharmaceuticals
*Organization & Developments: Bluebird (Archives 2014 - 2018)
*The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted.
2019: Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy
2019: Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease
2019: bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD_seekingalpha.com
2020: bluebird bio Should Be On Your Radar With Multiple Catalysts Expected This Year And 2021
2020: Prognosis For A CAR-T Pioneer_seekingalpha.com
2021: After Many Delays, BMS and bluebird Win Approval for Multiple Myeloma CAR-T
2021: Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag
2021: bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
2021: bluebird bio: Waiting For The Dust To Settle
2021: Bluebird spins itself into two companies, severing gene therapy and cancer units
2021: It's official: FDA clamps a hold on bluebird's troubled LentiGlobin program while EMA considers new measures
2022: A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona
2022: Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US
2022: bluebird bio: Commercial Success Highly Uncertain_ seekingalpha.com
2022: Wobbly and desperate for cash, bluebird bio eyes 'cost efficiencies,' priority review voucher sale from future approvals
2023: After delays, bluebird's sickle cell gene therapy finally lands at the FDA's desk
2023: bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD_ seekingalpha.com
2023: Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment_seekingalpha.com
2023: FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
2024: bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
2024: Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat
2024: bluebird bio shares jump on first outcomes-based Medicaid deal for sickle cell therapy
2024: Bluebird Bio: Innovative Therapies, Monetary Setbacks
2024: bluebird bio: Scientific Success And Financial Success, And The Gap Between_ seekingalpha.com
2024: Bluebird to lay off another 25% of workforce in latest restructuring
2024: CMS names two drug manufacturers for cell and gene therapy model
2024: New data underline cancer risk of Bluebird therapy for brain disease
2024: Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
2025: Cell and Gene Therapy Access Model is excited to announce the 33 states participating ... New CMS Payment Model Launched for Sickle Cell Gene Therapy
2025: StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Jumps
*Key People: Bluebird
Finance & Acquisitions: BlueBird